Epigenetic Modification of FOXP3 in Patients with Chronic HIV Infection
Overview
Affiliations
Objectives: HIV-1 modulates host cell epigenetic machinery to control its own replication and induce immune suppression. HIV-1 infection leads to activation of T regulatory cell (T(reg)), but the mechanism underlying this immune modulation is unclear. T(reg) plays a prominent role in gut-mucosal immune tolerance by restraining excessive effector T-cell responses, a mechanism that is known to be disturbed in chronic HIV-1 infection. DNA methylation plays a major role in T(reg) lineage commitment and immune homeostasis, which may be regulated by HIV. To investigate the mechanisms of aberrant methylation of the T(reg) marker FOXP3 in HIV-1 infection, we evaluated the expression pattern of methylation-related enzymes and its correlation to FOXP3 methylation.
Methods: FOXP3 promoter methylation in the colon mucosa and peripheral blood from HIV-infected patients and control subjects was measured using Pyrosequencing. Gene expression pattern of DNA methylation enzymes in the colon mucosa was investigated by Microarray and quantitative reverse transcriptase-polymerase chain reaction analysis in the same subjects.
Results: FOXP3 promoter was significantly (P ≤ 0.0001) demethylated in HIV-infected patients compared with control subjects in both tissues. Expression of DNA methyltransferase 1 (DNAMT1), DNA methyltransferase 1-associated protein 1(DMAP1), methyltransferase-like 7B (METTL7B), and methyltransferase-like 10 (METTL10) were significantly down regulated in HIV-infected patients compared with controls and had a significant positive correlation to FOXP3 promoter methylation.
Conclusions: We present evidence suggesting that altered methylation pattern of FOXP3 and accordingly higher T(reg) frequency in gut mucosa of HIV-infected patients may be because of aberrant methylation processing in HIV.
Huang D, Yan H Bioengineered. 2022; 13(5):11753-11766.
PMID: 35603523 PMC: 9275875. DOI: 10.1080/21655979.2022.2068892.
Deciphering DNA Methylation in HIV Infection.
Arumugam T, Ramphal U, Adimulam T, Chinniah R, Ramsuran V Front Immunol. 2021; 12:795121.
PMID: 34925380 PMC: 8674454. DOI: 10.3389/fimmu.2021.795121.
Chen X, Li C, Li Y, Wu S, Liu W, Lin T Front Mol Biosci. 2021; 8:727481.
PMID: 34604305 PMC: 8484875. DOI: 10.3389/fmolb.2021.727481.
METTL7B is a novel prognostic biomarker of lower-grade glioma based on pan-cancer analysis.
Jiang Z, Yin W, Zhu H, Tan J, Guo Y, Xin Z Cancer Cell Int. 2021; 21(1):383.
PMID: 34281539 PMC: 8287669. DOI: 10.1186/s12935-021-02087-4.
Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?.
Salahong T, Schwartz C, Sungthong R Viruses. 2021; 13(6).
PMID: 34072421 PMC: 8228869. DOI: 10.3390/v13061026.